BridgeMD
New treatment option for NASH - Nonalcoholic Steatohepatitis
Official title Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
ClinicalTrials.gov ID: NCT03587831
What this study is testing
- What it's testing
- Participants meeting study entry criteria are randomized with equal probability to one of two study groups: (1) Lifestyle modification or (2) Vertical Sleeve Gastrectomy (VSG) with Iifestyle modification, followed for 12 months. The primary goal for the trial is to determine if the investigators can recruit, randomize, and retain participants to perform invasive and non-invasive measurements of NASH and fibrosis, deliver lifestyle modification and demonstrate the safety of VSG.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 70
You may be able to join if
- Age 30 to 70 years at eligibility visit.
- At least one of the following:
- Diagnosed with NASH with a total NAS ≥ 4 including a ballooning score of at least 1
- Diagnosed with T2DM or prediabetes, HbA1c\< 9%
- Body Mass Index (BMI): 35.0-60.0 kg/m2 at eligibility visit.
You likely can't join if
- Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months.
- Current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease.
- Pulmonary embolus or thrombophlebitis in the past six months.
- Cancer of any kind (except basal cell skin cancer or cancer in situ) unless documented to be disease-free for five years.
- Significant anemia (hemoglobin 2.0 g/dL or more below normal range) or history of coagulopathy. (Low range for women would be 10, low range for men...
- Serum creatinine \>1.8 mg/dL.
See the full eligibility criteria
- Age 30 to 70 years at eligibility visit.
- At least one of the following:
- Diagnosed with NASH with a total NAS ≥ 4 including a ballooning score of at least 1
- Diagnosed with T2DM or prediabetes, HbA1c\< 9%
- Body Mass Index (BMI): 35.0-60.0 kg/m2 at eligibility visit.
- Willingness to accept random assignment to either treatment group.
- All patients must have insurance with no exclusion for obesity related treatments or management of obesity surgery complications. This applies to all participants enrolled in the study
- Evidence of liver fat present in the baseline MR images
- Suitable for liver biopsy
- Willingness to comply with the follow-up protocol and successful completion of the run-in (described below).
- Written informed consent.
- English speaking
- Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months.
- Current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease.
- Pulmonary embolus or thrombophlebitis in the past six months.
- Cancer of any kind (except basal cell skin cancer or cancer in situ) unless documented to be disease-free for five years.
- Significant anemia (hemoglobin 2.0 g/dL or more below normal range) or history of coagulopathy. (Low range for women would be 10, low range for men would be 11)
- Serum creatinine \>1.8 mg/dL.
- Serum total bilirubin greater than the upper limit of normal in the absence of Gilbert's syndrome, or alkaline phosphatase or ALT or AST greater than 2.5x the upper limit of normal. Elevated INR.
- Alcohol intake more than one drink or \>20 grams per day
- History of stomach surgery, bile duct surgery, pancreatic surgery, splenectomy, or colon resection.
- Gastric or duodenal ulcer in the past six months.
- History of intra-abdominal sepsis (except for uncomplicated appendicitis or diverticulitis more than six months prior to enrollment).
- Previous organ transplantation.
- Self-reported HIV-positive status, active tuberculosis, active malaria, chronic hepatitis B or C, cirrhosis, or inflammatory bowel disease.
- Currently pregnant or nursing, or planning to become pregnant in the next two years.
- History of alcohol, drug, or opioid dependency (excluding nicotine) in the past five years.
- Active psychosocial or psychiatric problem that is likely to interfere with adherence to the protocol.
- A score of 17 or greater on the CES-D questionnaire administered on a typical week for the participant.
- Presence of any chronic or debilitating disease that would make adherence to the protocol difficult.
- Serum c-peptide \<1.0 ng/ml post prandial.
- Exclusions may also be made at the discretion of the attending physician or the eligibility committee.
- History of endoscopy demonstrating esophagitis or Barrett's changes in the esophagus.
- Any history of dysphagia.
- Fibrosis score \> 3
- Use of Rezdiffra (resmetirom).
The study team makes the final eligibility decision.
Where it's taking place
- San Francisco, California, United States
- Baton Rouge, Louisiana, United States
- Minneapolis, Minnesota, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include San Francisco, California, United States; Baton Rouge, Louisiana, United States; Minneapolis, Minnesota, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.